Clinical Pharmacology, Disease and Organic Chemistry

Antibody Drug Conjugates: windows of opportunity

Drug Target Review

JULY 4, 2023

In practice, some patients may be left managing a syndrome associated with the therapy along with the disease. In the ADC trial, the objective response rate (ORR) – defined as the percentage of patients whose disease decreased or disappears – was 42 percent whilst the ORR in the small molecule trial was 12.5

Small Molecule

Small Molecule Drugs Clinical Pharmacology Trials

Drug Discovery Digest

Antibody Drug Conjugates: windows of opportunity

Webinars

Stay Connected